STERIS STE Ratios & Valuation
| Q4 '26 | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | ||
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | 44.2%+0.2pp | 44.1%+0.7pp | 44.3%+1.2pp | 44.1%+0.9pp | 44%+0.8pp | |
| Operating margin | 18.6%+2.7pp | 17.2%+1.0pp | 17.1%+1.1pp | 16.6%+0.9pp | 15.9%-0.4pp | |
| Net margin | 13.2%+1.9pp | 12.1%+3.5pp | 12.1%+3.9pp | 11.6%+4.0pp | 11.3%+3.9pp | |
| Returns | ||||||
| Return on equity | 11.3%+1.8pp | 10.4%+3.1pp | 10.1%+3.3pp | 9.7%+3.3pp | 9.5%+3.4pp | |
| Return on invested capital | 9.4%+2.1pp | 8.8%+1.3pp | 8.5%+1.1pp | 8.2%+0.8pp | 7.3%+0.2pp | |
| Efficiency | ||||||
| Asset turnover | 0.6×+0.1× | 0.6×+0.1× | 0.6×+0.1× | 0.5×0.0× | 0.5×0.0× | |
| Liquidity | ||||||
| Current ratio | 2.1×+0.1× | 2.5×+0.3× | 2.4×0.0× | 2.2×-0.1× | 2×-1.1× | |
| Leverage | ||||||
| Debt-to-equity | 0.3×-0.1× | 0.3×-0.1× | 0.3×-0.1× | 0.3×-0.1× | 0.4×-0.2× | |
| Net debt / EBITDA | 1×-0.6× | 1×-0.6× | 1.1×-0.5× | 1.2×-0.5× | 1.6×-0.7× | |
| Valuation | ||||||
| Market capitalization | $21.69B-2.6% | $24.88B+22.6% | $24.37B+1.6% | $23.57B+8.6% | $22.27B+0.3% | |
| Price / earnings | 27.7×-8.5× | 35.2×-8.2× | 35.4×-19.8× | 36.5×-17.8× | 36.2×-22.5× | |
| Price / sales | 3.7×-0.4× | 4.3×+0.5× | 4.3×-0.2× | 4.2×+0.1× | 4.1×-0.2× | |
| Price / book | 3×-0.4× | 3.5×+0.3× | 3.5×-0.2× | 3.4×0.0× | 3.4×-0.2× | |
| EV / EBITDA | 14.7×-3.5× | 17.8×+1.2× | 17.8×-1.5× | 17.9×+0.3× | 18.2×0.0× | |
| Dividend yield | 1.1%+0.1pp | 0.9%-0.1pp | 0.9%+0.1pp | 1%0.0pp | 1%+0.1pp |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are STERIS's profit margins?
- STERIS (STE) runs a 44.2% gross margin and a 18.6% operating margin, with a 13.2% net margin.
- Where do STERIS's ratios come from?
- Every ratio is computed from STERIS's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
